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Clinically amyopathic dermatomyositis (CADM), a subtype of dermatomyositis (DM), is characterized as
having the classic cutaneous manifestations of DM but with little or no evidence of myositis. The
presence of anti-melanoma differentiation associated gene 5 (anti-MDA-5) autoantibodies, in the setting
of CADM, is associated with rapidly progressive interstitial lung disease (RPILD). The use of extracor-
poreal membrane oxygenation (ECMO) in patients with RPILD has been well described in adults, but not
in children. Herein we present a 14-year old patient with interstitial lung disease, initially of unknown
etiology, whom we supported with ECMO in the acute phase of her illness for nearly two months during
which the diagnosis of anti-MDA-5 dermatomyositis was established.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Clinically amyopathic dermatomyositis (CADM), a subtype of
dermatomyositis (DM), was ﬁrst described by Sontheimer in 2002,
and is characterized as having the classic cutaneous manifesta-
tions of DM but with little or no evidence of myositis [1]. The
presence of anti-melanoma differentiation associated gene 5
(anti-MDA-5) autoantibodies, in the setting of CADM, is associated
with rapidly progressive interstitial lung disease (RPILD) and has
a poor prognosis with high rates of mortality [2]. The use of
extracorporeal membrane oxygenation (ECMO) in patients with
RPILD has been well described in adults, but not in children.
Herein we present a 14-year old patient with interstitial lung
disease, initially of unknown etiology, whom we supported on
ECMO in the acute phase of her illness for nearly two months
during which the diagnosis of anti-MDA-5 dermatomyositis was
established.rgery, Columbia University
, New York, NY 10032, USA.
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Inc. This is an open access article u1. Case report
A 14-year old female patient, with a 3 month history of pro-
gressively worsening constitutional symptoms including dyspnea,
fever, and a 35-pound weight loss, was transferred to our institu-
tion for an ECMO evaluation after developing acute respiratory
distress syndrome (ARDS) requiring intubation, mechanical venti-
lation, and chest tube placement for bilateral pneumothoracies. Her
past medical history included mild intermittent asthma, but was
otherwise unremarkable. Chest radiograph at our institution
demonstrated dense consolidations bilaterally consistent with
pneumonia (Fig 1). Computerized tomography (CT) scan of the
chest showed diffuse patchy bilateral airspace disease, extensive
pneumomediastinum and subcutaneous emphysema (Fig 2). Flex-
ible bronchoscopy revealed diffuse blood in the small airways
consistent with the evolution of ARDS, and a lung biopsy showed
organizing, diffuse alveolar damage with hyaline membrane and
ﬁbrin plug formation. She was hypoxemic and unable to be
adequately ventilated on conventional ventilator. Thus, high fre-
quency oscillator ventilation (HFOV) with inhaled nitric oxide was
initiated. Despite the increased support, her respiratory status
worsened and on hospital day 13, veno-venous ECMO (VeV ECMO)nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Diffuse prominence of the lung markings with patchy opacities right greater
than left. Elevation of the right hemidiaphragm. Pneumomediastinum and subcu-
taneous emphysema.
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percutaneous approach in the right internal jugular vein. After
stabilization on VeV ECMO, a bedside percutaneous tracheostomy
was performed.
Although initially the etiology of her lung disease was unknown,
a rheumatologic workup, including a myositis panel and anti-
synthestase testing, revealed that our patient was positive for
anti-MDA-5 autoantibody. A rheumatologic workup was indicated
because her serum aldolase level was elevated on presentation.
With no prior history of myositis, our working diagnosis was
interstitial lung disease as a complication of clinically amyopathicFig. 2. Diffuse patchy bilateral airspace disease, right greater than left. Imaging char-
acteristics are nonspeciﬁc, with differential considerations including multifocal infec-
tious process, pulmonary hemorrhage, or ﬁndings associated with an additional
systemic process. Extensive pneumomediastinum and subcutaneous emphysema.dermatomyositis with presence of anti-MDA-5 autoantibodies.
However, her presentation was atypical as there was no evidence
of cutaneous involvement or vasculopathy. On hospital day 41,
she was started on immunosuppressive therapy including pulse
steroids, intravenous immunoglobulin (IVIG), tacrolimus, and rit-
uximab. In addition, she received 5 rounds of plasmapheresis. Her
family deferred muscle biopsy, but ultrasound of the left deltoid
showed no evidence of myositis. During immunosuppressive
therapy, while on ECMO, her respiratory and cardiac status slowly
improved. She was eventually weaned from high frequency
oscillation to a conventional ventilator, and on hospital 69, she
was decannulated from ECMO after a 55-day total run.
Three weeks after ECMO support was discontinued, the patient’s
clinical status abruptly deteriorated. She developed aspiration
pneumonia and went into septic shock and acute renal failure.
Blood cultures at that time were positive for acinetobacter bau-
mannii. Broad-spectrum antibiotics were subsequently initiated.
She was placed back on HFOV and inotropes were started. Echo-
cardiogram showed severely diminished right ventricular function.
Seizure activity was also noted and an electroencephalogram (EEG)
showed epileptic potential in the left frontal-temporal region and
severe slowing. She had absent brain stem reﬂexes on exam. After
an inter-disciplinary family meeting, care was withdrawn and the
patient expired. Family refused autopsy.
2. Discussion
CADM-associated interstitial lung disease, in the setting of anti-
MDA-5 antibodies, is a life threatening complication of dermato-
myositis with mortality rates nearing 60%, [2]. The difﬁculty in
establishing the diagnosis of CADMoften leads to a delay in therapy.
The detection of anti-MDA-5 autoantibodies is useful in predicting
and monitoring response to treatment, [3]. In our patient with
ARDS, CADM was not initially considered as her presentation was
atypical. There was no evidence of cutaneous involvement or a
history of myositis that is normally associated with classic CADM.
To complicate matters, her clinical course deteriorated rapidly and
confounded her diagnosis. Initiating ECMO to treat her ARDS, and
ultimately serve as a bridge to her diagnosis, was critical. The
mortality rate of pediatric patients with ARDS, who have become
refractory to conventional respiratory ventilation, exceeds 90%.
With ECMO, however, survival to hospital discharge for pediatric
patients with severe respiratory failure is 56%, [4]. Our early man-
agement strategy was to support the patient with ECMO therapy
until a diagnosis was established.
Given the acute onset and decompensation of our patient, with
respect to her age and lack of previous signiﬁcant medical history,
ECMO was instituted immediately once she met institutional
criteria. Once ECMO was instituted, the palliative care team was
consulted to help mediate ethical conversations between the
intensivists, medical subspecialists and the patient’s family. The
collaborative medical team thoroughly discussed the use of ECMO
as a bridge to diagnosis with our patient’s parents. It was the
parents wish to support their daughter on ECMO as long as
necessary to establish a diagnosis provided she was not decom-
pensating further or suffering in pain. The medical team agreed
with this plan.
The presence of anti-MDA-5 autoantibodies was detected
through enzyme-linked immunosorbent assay (ELISA) testing 28
days after we instituted ECMO and approximately 4 months after
her initial symptoms. She remained on ECMO, undergoing intense
immunosuppressive therapy, for an additional 27 days before we
discontinued ECMO for a total run of 55-days.
Outcomes are generally favorable with short term ECMO
therapy, but prolonged ECMO therapy in children with refractory
R. Mejias et al. / J Ped Surg Case Reports 9 (2016) 31e33 33pulmonary failure is associated with low survival and signiﬁcant
long-term sequelae, [5]. Although our patient ultimately suc-
cumbed to her illness, her prolonged survival on ECMO was the
result of a proactive and multidisciplinary approach from the
ECMO service, the intensivists, and all consulting services.References
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